



January 28, 2015

The Dy. General Manager (Listing Dept.)
Bombay Stock Exchange Limited
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager - Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai - 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Submission / Intimation under Listing Agreement on:

- (1) Financial Results for the quarter/ half year ended on 31st December, 2014;
- (2) Declaration of Interim Dividend & pay out date;
- (3) Recommendation to shareholders for issuance of Securities; and
- (4) Extension of term of Dr. Chaitanya Dutt, Director (Research & Development) as whole-time director.

1) With reference to above captioned subjects, we enclose herewith the following:

- (a) Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter and nine months ended on 31st December, 2014 as per clause 41 of the Listing Agreement, which were approved by the Board of Directors at its meeting held on 28th January, 2015.

In terms of clause 41(VI) (b) of the Listing Agreement, the Company will publish above Unaudited Consolidated Financial Results for the quarter and half year ended on 31st December, 2014. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com.

- (b) Press Release on Financial Results as being submitted to the press media.

- 2) We would like to inform, pursuant to clause 20 read with clause 20A of the Listing Agreement, that the Board of Directors at the above meeting has also declared an interim dividend of ₹ 5/- per equity share of ₹ 5/- each fully paid up. These dividend amounts will be paid / dispatched on 10th February, 2015.



Contd.

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26585090 www.torrentpharma.com



-2-

3) We would also like to intimate, pursuant to Clause 22 and Clause 36 of the Listing Agreement, that the Board has at the aforesaid meeting decided to obtain enabling approvals, from the shareholders inter alia, for issuance of following securities through postal ballot process:-

- I) Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes for an amount not exceeding ₹ 3,000 crores; and
- II) Unsecured / Secured Redeemable Non-Convertible Debentures / Bonds by way of Private Placement for an amount not exceeding ₹ 7,500 crores, subject to the overall borrowing limits of ₹ 10,000 crores as proposed.

Copy of the Postal Ballot Notice etc. on the aforesaid proposals will be sent to your exchange in due course, prior to dispatch of the same to the shareholders.

4) Pursuant to Clause 30 (a) of the Listing Agreement, we hereby notify that the Board of Directors at their above meeting has also approved extension of term of Dr. Chaitanya Dutt, Director (Research & Development) as whole-time director for a period of three years commencing from 01st January 2015, in place of two years as approved earlier, on revised terms and conditions including the remuneration.

The above are for your information and record please.

Thanking you,

Yours faithfully,

For TORRENT PHARMACEUTICALS LIMITED

A handwritten signature in black ink, appearing to read 'Mahesh Agrawal'.

MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: A/a

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26585090 www.torrentpharma.com